Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-30
2005-08-30
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S229800, C514S230500, C514S266300, C514S267000, C514S373000, C514S416000, C544S054000, C544S089000, C544S091000, C544S092000, C544S250000, C544S286000, C548S212000, C548S472000
Reexamination Certificate
active
06936606
ABSTRACT:
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds
REFERENCES:
patent: 5776718 (1998-07-01), Palmer et al.
patent: 6395897 (2002-05-01), Cywin et al.
patent: 6420364 (2002-07-01), Emmanuel et al.
patent: 2003/0158256 (2003-08-01), Cowen et al.
patent: WO 99/24460 (1999-05-01), None
patent: WO 00/55125 (2000-09-01), None
patent: WO 00/55126 (2000-09-01), None
patent: WO 01/19796 (2001-03-01), None
patent: WO 01/19808 (2001-03-01), None
patent: WO 01/19816 (2001-03-01), None
Marquis, Robert W., Ann. Reports Med. Chem., vol. 35, pp. 309-320, 2000.
Rasnick et al “Small synthetic inhibitors of cysteine proteases”; Perspectives in Drug Discovery and Design, vol. 6, pp. 47 63 (1996).
Riese R.J. et al, J. Clin. Invest., 101(11), pp. 2351-2363, 1998.
Saegusa K,, et al, J. Clin Invest. Aug. 2002;110(3):361-9.
Thurmond RL et al, J Pharmacol Exp Ther. Oct. 17, 2003, abstract cited in PMID: 14566006.
Vitas-M Screening Collection, Mar. 22, 2001, cited in Chemical Abstracts, 2001:473994 CHEMCATS.
Robin L. Thurmond, et al; Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor; Journal of Pharmacology and Experimental Therapeutics, vol. 308, No. 1 pp 268-276.
H. Beck, et al; Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro; Eur. J. Immunol., 2001, 31: 3726-3736.
Terry Y. Nakagawa, et al; Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-induced Arthritis in Cathepsin S Null Mice; Immunity, vol. 10, 207-217, Feb. 1999.
Francesca Lazner, et al; Osteropetrosis and Osteoporosis: two sides of the same coin; Human Molecular Genetics 1999, vol. 8 No. 10 Review 1839-1846.
Galina K. Sukhova, et al; Expression of the Elastolytic Cathepsins S and K in Human Atheroma and Regulation of their Production in Smooth Muscle Cells; J. Clin. Invest. vol. 102, No. 2, Aug. 1998, pp. 576-583.
Harold A. Chapman, et al; Emerging Rofes for Cysteine Proteases in Human Biology; Annu. Rev. Physiol. 1997, 59, 63-88.
Ulf Mueller-Ladner, et al; Cysteine Proteinases in Arthritis and Inflammation: Perspectives in Drug Discovery and Design, vol. 6, pp. 87-98.
Woomi Kim and Kooli Kang; Recent developments of Cathepsin Inhibitors and Their Sensitivity; Expert Opinion Ther. Patents (2002) 12(3), pp 421-432.
Revised by Richard J. Lewis, Sr., Hawley's Condensed Chemical Dictionary, Thirteen Edition, pp 515-516.
Bekkali Younes
Hickey Eugene R.
Liu Wei-min
Patel Usha R.
Spero Denice Mary
Boehringer Ingelheim Pharmaceuticals Inc.
Bottino A. P.
Datlow P. I.
McKenzie Thomas C.
Morris M. P.
LandOfFree
Cyanoamido-containing heterocyclic compounds useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyanoamido-containing heterocyclic compounds useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanoamido-containing heterocyclic compounds useful as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3507291